LIANY · LianBio
Market Cap
$5.30M
Shares
108.06M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.06
Open$0.06
Day$0.06–0.06
52W close$0.03–0.18
Avg vol 30d46K
Short int10K · 0.0% float · 1.0d
Short vol100%
DataNov 2021–Sep 2026
Filing10-Q · Nov 13
Up next
filed Nov 13, 2023
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$87.98M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1,586.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$252.22M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-1.1%
Year over year · fewer shares
Price change (1Y)
+10.2%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−30%
below
Price vs 50-day avg
−25%
below
RSI (14)
53
neutral
MACD trend
Positive
52-week position
19%
mid-range
Volume (OBV)
Bearish div.
distributing
Momentum
relative strength
1-month return
+24%
trailing
6-month return
−20%
trailing
YTD return
−37%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.01% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Squeeze score
25
low risk · 0–100
Fundamentals
EPS growth
+82%
Y/Y
Free cash flow
$-101.0M
Quant / Vol
risk profile
Volatility
225%
annualized · 1-yr
Max drawdown
−93%
past year
ATR
18.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−30%
Bearish
Price vs 50-day avg
−25%
Bearish
RSI (14)
53
Neutral
MACD trend
Positive
Bullish
52-week position
19%
Neutral
Volume (OBV)
Bearish div.
Bearish
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $0 › 200d $0 — 200d above 50d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.01% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 19%
Range high $0
vs 200-day avg -30%
vs 50-day avg -25%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LIANY
this stock
LianBio
|
$5.30M | -37.4% | — | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$130.06B | +13.9% | +46.2% | 29.9 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$79.83B | +2.3% | +20.8% | 19.2 | 2.5% |
|
ARGX
Argenx SE
|
$60.93B | +18.4% | — | — | 2.0% |
|
CSLLY
Csl Ltd
|
$59.64B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LIANY | +48.8% | +24.0% | -19.6% | +48.8% | -37.4% |
| SPY | -1.1% | -2.0% | +16.0% | -1.3% | +11.1% |
| vs SPY | +49.9% | +25.9% | -35.5% | +50.0% | -48.4% |